A structured look at why CEOs keep investing in marketing fixes — and why growth stays flat.

Here is a pattern I have seen enough times that it no longer surprises me.

A CEO calls. The company is doing $15 million in revenue, has been growing for years on referrals, and is now watching that engine slow. They have hired an agency. They have redesigned the website. They have run ads. They have posted on LinkedIn. None of it has produced the kind of demand they expected.

The CEO is not naive. He knows something is wrong. What he does not know is whether the problem is the marketing — or whether it is something structural that no amount of marketing spend will fix.

That question is the reason a fractional CMO diagnostic exists.

The most expensive mistake I see at this stage is not bad marketing. It is investing in more marketing before anyone has determined whether the function is governed at the executive level.

Most companies at this revenue level have never had a formal marketing leadership structure. Growth happened because the founder was good at sales, because the product was genuinely differentiated, or because the market was expanding. Marketing was always the thing they would get to later.

Later is now. And the tools they reach for — agencies, consultants, campaigns, rebrands — are all tactical answers to what is often a structural problem.

What Is a Fractional CMO Diagnostic?

A fractional CMO diagnostic is a structured, time-bound executive evaluation. It does not produce a list of marketing recommendations. It produces a verdict.

Specifically, it answers one question: is marketing leadership the primary constraint on this company’s growth — or is the bottleneck somewhere else?

That distinction matters more than most CEOs realize. If the constraint is structural — no executive ownership of growth, no accountability framework, no defined demand process — then hiring another agency will not move the number. Neither will a new CRM, a rebrand, or a content calendar.

If the constraint is elsewhere — in sales capacity, product gaps, or operational ceiling — then the CEO needs to know that too, before committing another dollar to marketing.

What a Fractional CMO Diagnostic Is Not

It is not a marketing audit. An audit evaluates tactics and execution quality. A diagnostic evaluates whether the marketing function is structurally capable of producing predictable demand at the executive level.

It is not a discovery call for a service contract. An honest diagnostic documents its findings in writing — including the finding that marketing leadership is not the primary constraint, when that is the case.

It is not a strategy session. The output is a verdict, not a roadmap.

What the Diagnostic Actually Evaluates

There are three structural questions that determine whether marketing is capable of driving predictable growth in a founder-led company. A fractional CMO diagnostic is built around all three.

1. Who owns growth at the executive level?

This is the question most companies cannot answer cleanly. Not who manages the marketing coordinator. Not who approves the ad spend. Who owns revenue momentum as an executive responsibility — and can be held accountable for it against a financial outcome?

In my experience, when I ask this question of a $20M company, the honest answer is usually: the CEO. Which means marketing is being delegated downward while accountability stays at the top. That gap is not a personnel problem. It is a governance problem.

2. Is demand generation intentional or episodic?

There is a meaningful difference between a company that generates leads and a company that has a demand system. The first produces results when someone is working it. The second compounds over time regardless of who is in the seat.

Most companies in the $5M to $50M range have the first. Campaigns run when someone has bandwidth. Content happens when someone has an idea. Referrals come in when a client is happy. None of it is structured to produce predictable pipeline.

A B2B marketing diagnostic determines whether the company has an actual growth engine — or a collection of marketing activities that happen to sometimes produce revenue.

3. Is marketing connected to financial outcomes?

The third dimension is governance and accountability. Can the CEO evaluate marketing spend against revenue impact? Is there executive-level reporting that informs capital allocation decisions — or are there dashboards full of clicks and impressions that no one in finance takes seriously?

If marketing cannot speak the language of finance, it will always lose the budget conversation. And the CEO will always be guessing whether the spend was worth it.

If you cannot measure marketing at the P&L level, you cannot govern it. And if you cannot govern it, you cannot scale it.

Why a Diagnostic Produces a Different Answer Than an Audit

A marketing audit is a backward-looking evaluation. It tells you whether the campaigns were built correctly, whether the SEO is sound, whether the email sequences are optimized. It is a quality review of work that has already been done.

A fractional CMO diagnostic is a forward-looking structural assessment. It tells you whether the function is capable of producing what the company needs next — not whether what has been done so far was good.

	Marketing Audit	Fractional CMO Diagnostic
Focus	Tactics and execution	Leadership structure and governance
Output	Recommendations list	Executive verdict in writing
Question answered	Was the work done well?	Can the function produce predictable growth?
Decision it supports	What to improve	Whether to invest in marketing leadership
Independence	Often tied to next engagement	Conclusion stated regardless of outcome

The distinction is not academic. A CEO who commissions a marketing audit after slow growth is likely to receive a recommendation to do more marketing. A CEO who commissions a fractional CMO diagnostic may receive a very different answer — and a much cleaner basis for the next decision.

What You Receive at the End of 30 Days

The Executive Marketing Readiness Review is a 30-day process. It produces three specific outputs:

1. An independent diagnostic analysis — a structured review of the company’s marketing leadership, demand system, and accountability framework against a defined evaluation standard.
2. A live executive briefing — a working session with the CEO and one key leader focused on interpreting findings and establishing priorities, not presenting a sales proposal.
3. A written executive marketing overview — a durable, company-specific summary of findings and the explicit determination: whether marketing leadership is the primary growth constraint, and what that means for the next decision.

The written report documents the verdict in plain language. If marketing leadership is the constraint, that is stated. If it is not, that is stated too — including what the data suggests is the more likely constraint.

That independence is structural. This is not a discovery call with a follow-up proposal. It is a diagnostic with a written conclusion.

What This Has Looked Like in Practice

Goelzer Industries was a 38-year-old manufacturer with zero formal marketing history when we started. The diagnostic confirmed what the CEO suspected: marketing leadership was the constraint, and the company had no demand system at all. Within the first engagement, we built a 38-page strategic marketing plan, drove 5,000-plus monthly website visits, and doubled the client base — while eight to nine competitors exited the market.

The diagnostic did not produce those results. It produced the clarity that made the right investment possible. Without it, the CEO would have been choosing between agencies with no framework for evaluating what he actually needed.

At Elite Health Online, the same principle applied. Monthly new patients grew from 70 to 188. Website sessions surged from 5,300 to 51,000 monthly. But the reason those results were achievable was that the diagnostic had determined, first, what was actually constraining growth — and what would happen if marketing leadership was established properly.

The diagnostic did not produce those results. It produced the clarity that made the right investment possible.

Signs This Diagnostic Is the Right Next Step

This review is designed for founder-led and CEO-led B2B companies between $5M and $50M in revenue. It is most relevant when:

• Growth has been inconsistent for two or more quarters and the root cause is not clearly identified
• Referrals have been the primary growth driver and that pipeline is slowing
• The company has worked with two or more agencies in the past three years without a durable improvement in revenue momentum
• Marketing activity is visible but the CEO cannot connect it to a financial outcome
• The CEO is still the primary growth decision-maker and that is creating a bandwidth problem

If none of those apply, this diagnostic is not the right tool. That is worth saying plainly.

If two or more apply, the cost of not knowing is almost certainly larger than $3,500.

How to Apply for the Review

The Executive Marketing Readiness Review is limited to five engagements per quarter. The process begins with a brief call to confirm fit — not a sales pitch.

If the fit is right, the 30-day evaluation begins. You receive a written verdict at the end. If the findings do not produce a clear, defensible determination of whether marketing leadership is the growth constraint, you may request a full refund.

Apply here

About Mark Toney

Mark Toney is a Fractional CMO and the founder of Luce Media. He has served in fractional CMO roles across six B2B organizations, building growth engines from scratch and helping CEOs determine whether marketing leadership is the structural constraint on their next stage of growth. He works with companies in manufacturing, healthcare, and B2B services in the $5M to $50M revenue range.